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ABSTRACT 
Background: Chronic venous leg ulcers (VLU) pose a significant burden to healthcare 
systems and predicting wound healing is challenging. The aim of this study was to develop a 
genetic test to evaluate the propensity of a chronic VLU to heal.  
Methods: Sequential refinement and testing of a gene expression signature was conducted 
utilising three distinct cohorts of human wound tissue. The expression of candidate genes 
were screened using a cohort of acute and chronic wound tissue and normal skin with 
quantitative transcript analysis. Genes showing significant expression differences were 
combined and examined, using Receiver Operator Curve (ROC) analysis, in a controlled 
prospective study of patients with VLU. A refined gene signature was evaluated using a 
prospective, blinded study of consecutive patients with VLU. 
Results: The initial gene signature, comprising 25 genes, could identify the outcome (healing 
vs. non-healing) of chronic VLUs (Area Under Curve (AUC) = 0.84, 95 per cent c.i. 0.73 to 0.94). 
Subsequent refinement resulted in a final 14 gene signature (WD14), which performed 
equally well (AUC = 0.88, 95 per cent c.i. 0.80 to 0.97). When examined in a prospective 
blinded study the WD14 signature could also identify wounds likely to demonstrate signs of 
healing (AUC = 0.73, 95 per cent c.i. 0.62 to 0.84).  
Conclusion: A gene signature can identify people with chronic venous leg ulcers that are 
unlikely to heal.
 
 
INTRODUCTION 
Successful wound healing requires the progression of a well described sequence of events; 
inflammation, angiogenesis, proliferation and cellular migration1,2. Failure of this process is 
not uncommon, due to a variety of systemic and local factors3. These resultant chronic 
wounds pose a significant health challenge, resulting in morbidity and a reduced quality of 
life4, whilst costing the National Health Service up to 6 per cent of its annual budget5.  
Recently, an increasing volume of research has examined and documented aberrations 
within the cell populations surrounding chronic wounds, assuming that disturbances in 
normal wound healing can be traced to perturbations in gene expression following injury.  
Using a variety of methodologies, cellular changes have been described that are similar 
across a range of wound aetiologies, such as reduced cellular motility, cellular senescence, 
and excessive inflammation6. Associated alterations at a genetic level have been noted, 
examined either individually or collectively. Data to predict which wounds are likely to heal 
is lacking.  
The aim of this study was to develop a wound healing score which can predict wound 
outcomes.12.  
 
 
 
METHODS 
Study design 
Three distinct patient cohorts were utilised to create and validate a wound-edge gene 
signature predictive of wound healing potential (Table 1, Figure 1).  Wound edge tissues 
from healing/acute wounds were compared with non-healing/chronic wounds and normal 
skin, and molecular markers found to be significantly different were analysed further. 
Research ethics approval was obtained for each patient cohort, and patients were enrolled 
after providing informed written consent.  
The ‘Screening cohort’), comprised patients with acute surgical wounds following excision of 
pilonidal sinus disease), chronic venous leg ulcers (VLUs) and skin samples from healthy 
volunteers (Table S1)13. Some 121 potential candidate genes (Table S2) were selected for 
screening based on their role in cellular processes essential for successful wound healing. 
Genes demonstrating significant expression differences between tissue types were 
identified and classified as either wound healing promoters or inhibitors, whilst genes 
showing no difference in expression were not analysed further. The presence of a gene 
promoting wound healing (or the absence of a gene inhibiting wound healing; Table S3) was 
considered a score of one.   The summation resulted in the initial gene signature score. A 
cut-off value was selected, with scores greater than this considered indicative of a 'healing' 
score.  
The second retrospective cohort (the ‘validation cohort’) comprised patients with VLUs  
undergoing wound edge biopsies as part of a controlled prospective study evaluating a 
range of biomarkers on ulcer prognosis, as previously reported14. After 12 weeks of 
 
 
standard best medical care, as prescribed by a senior wound healing clinician, wounds were 
classified as healed or non-healed. The initial gene signature score was calculated for each 
patient, and compared to the actual clinical outcome. Refinement of the gene signature was 
undertaken by assessing the prognostic ability of each individual gene.  Individual genes 
least able to distinguish healed and non-healed wounds underwent stepwise removal, 
starting with the least different gene.  The remaining genes, able to distinguish healed from 
non-healed wounds, were combined as the final gene signature (Table S4).   
The third cohort (the ‘study cohort’), comprised a prospective, blinded study enrolling 
consecutive patients with VLUs referred to a tertiary wound healing unit (Table S5)15. 
Wound edge biopsies were obtained at the initial visit. After 12 weeks of standard best 
medical care, as prescribed by a senior wound healing clinician, wound outcomes were 
recorded. Tissue specimens underwent blinded batch testing using the refined gene 
signature. Predicted outcomes from the gene signature were compared to actual clinical 
outcomes.  Important clinical parameters (age, smoking status, wound duration at entry to 
study and wound infection during study period) known to affect wound healing were 
captured and examined alongside the gene signature. 
 
Exclusion and inclusion criteria and clinical assessment of wound healing 
For all cohorts, VLUs, showing clinical features consistent with underlying venous disease, 
were diagnosed by a senior wound healing physician at a tertiary wound healing centre. 
Inclusion criteria included the presence of a lower limb VLU for a minimum of three months 
despite standard medical care, age >18 years, and a wound size of >2cm2 and <100cm2. 
 
 
Patients with obvious signs of infection, concomitant peripheral arterial disease (Ankle 
Brachial Pressure Index < 0.8), malignancy, autoimmune wounds, patients receiving 
systemic immunosuppression or chemotherapy and where ulcer aetiology was uncertain, 
were excluded. Patients in the validation and study cohort who failed to attend their follow-
up clinics were also excluded. All patients in the study cohort had concurrent histological 
examination of their wound biopsy to exclude occult neoplastic or autoimmune disease. 
Wound care was personalised for each patient, with wounds being systematically treated as 
per the TIME (Tissue, Infection/Inflammation, Moisture, Edge) wound bed preparation 
approach2,16. Topical antimicrobials or antibiotics were prescribed as required in the event 
of an episode of clinical wound infection. Graduated multi component bandaging systems 
were used to compress the limb consistent with international guidelines.  Wound area was 
assessed by specialist wound care nurses at each visit.  Surgery for superficial venous 
incompetence was not performed in the presence of an active ulcer; patients suitable for 
treatment were referred to the appropriate specialist once healing was obtained. 
 
Methods of biopsy and tissue processing 
Prior to biopsy, all patients were assessed for bleeding risk and, where required, 
anticoagulation was stopped before the procedure.  Antiseptic cleansing was used at the 
biopsy site and a 6mm core biopsy was taken from the wound edge, capturing both wound 
base and the leading keratinocyte edge, under local anaesthesia (1 per cent lignocaine). 
Haemostatic dressings were applied until the next dressing change. Antibiotics were not 
routinely prescribed.   
 
 
Biopsies were immediately frozen in dry ice before being transferred to a -80oC freezer until 
batch analysis was undertaken. Specific details of the analysis are provided in 
supplementary material.   
 
Statistical analysis  
Data analyses were undertaken using Minitab version 14.0 (Minitab Inc., Coventry, UK), 
SPSS version 18 (SPSS Inc, Chicago, Ill, USA) and SigmaPlot 11 (Systat Software Inc., London, 
UK) with P values ≤0.05 considered statistically significant. The gene transcript expression 
from the screening cohort were analysed using a Kruskal Wallis test.  Receiver Operator 
Curve (ROC) area under curve (AUC) analysis of the gene signature was undertaken, and are 
presented with their 95 per cent confidence intervals (c.i.). Sensitivities, specificities and 
likelihood ratios are reported for the pre-determined signature cut off values and are given 
with their 95 per cent c.i.  
For the study cohort, a binary logistic regression calculation was used to assess if the final 
gene signature and other clinical parameters, were predictive of the final clinical state. 
Univariate factors with a P value ≤0.1 were carried forward to a multivariate model, with 
P≤0.05 considered statistically significant in the final model. 
  
 
 
RESULTS 
Gene expression screening and creation of the WounD25 (WD25) gene signature  
The screening cohort comprised 34 patients with acute surgical wounds following excision 
of pilonidal sinus disease (n=10), chronic VLUs, (n=14) and skin samples from healthy 
volunteers (n = 10). Interrogation of the expression of the 121 candidate genes (Table S2) 
identified 25 genes able to differentiate between wound types (Table S3). Based on the 
gene expression, each gene was defined as a promoter or inhibitor of healing and scored as 
either 1 or 0, as detailed above.  These 25 gene scores were combined to form the WD25 
(WounD25) gene signature, with a value of >16 considered predictive of healing. The WD25 
gene signature was able to clearly distinguish acute from chronic wounds (ROC AUC: 0.95; 
95 per cent c.i. 0.86 to 1.03), with a sensitivity of 92.9 (95 per cent c.i. 66.1 to 99.8) per cent, 
a specificity of 90.0 (95 per cent c.i. 55.5 to 99.8) per cent a positive likelihood ratio (PLR) of 
9.29 (95 per cent c.i. 1.44 to 59.95) and a negative likelihood ratio (NLR) of 0.08 (95 per cent 
c.i. 0.01 to 0.53; Figure 2).  
 
WD14 gene signature creation  
The validation cohort comprised 71 participants with chronic VLUs undergoing wound edge 
biopsy.  After 12 weeks of standard best medical care 20 ulcers had healed (completely 
epithelialised) whilst 51 remained unhealed. The outcomes predicted by the WD25 were 
compared to clinical outcome.  The WD25 resulted in an AUC of 0.84 (95 per cent c.i. 0.73 to 
0.94; Figure 3a/c), a sensitivity of 92.2 (95 per cent c.i. 81.1 to 97.8) per cent, a specificity of 
 
 
55.0 (95 per cent c.i. 31.5 to 76.9) per cent, a PLR of 2.05 (95 per cent c.i. 1.25 to 3.35) and 
an NLR of 0.14 (95 per cent c.i. 0.05 to 0.40). 
The WD25 signature was further refined by assessing the contribution of individual genes to 
the model. This resulted in the stepwise removal of a further 11 redundant genes which 
failed to distinguish between wound type when assessed individually.  The remaining 14 
genes were combined as the WD14 (WounD14) gene signature (cut off score of >8; Table 
S4), and the predicted outcomes of each patient were re-calculated.  The WD14 gene 
signature was also able to distinguish between healing and non-healing chronic wounds 
with an AUC of 0.88 (95 per cent c.i. 0.80 to 0.97; Figure 3b/c), a sensitivity of 86.3 (95 per 
cent c.i. 73.7 to 94.3) per cent, a specificity of 70.0 (95 per cent c.i. 45.7 to 88.1) per cent, a 
PLR  of 2.88 (95 per cent c.i. 1.46 to 5.67) and an NLR of 0.20 (95 per cent c.i. 0.09 to 0.41). 
 
Predictive value of WD14 in patients with chronic venous leg ulcers as assessed in a 
prospective study 
A prospective, blinded, open study of the WD14 gene signature was undertaken in 85 
consecutive patients referred to a tertiary wound healing unit.   After 12 weeks, 41 wounds 
were classified as ‘healing’ (any reduction in wound size), whilst 44 were static or enlarging 
and classified as ‘non-healing’. Predicted outcomes from the WD14 were compared to 
actual outcomes.  WD14 remained a significant predictive tool for assessing healing 
potential (AUC = 0.73; 95 per cent c.i. 0.62 to 0.84; Figure 4), with a sensitivity of 63.6 (95 
per cent c.i. 47.8 to 77.6) per cent, a specificity of 85.4 (95 per cent c.i. 70.8 to 94.4) per 
 
 
cent, a PLR of 4.35 (95 per cent c.i. 2.01 to 9.41) and an NLR of 0.43 (95 per cent c.i. 0.28 to 
0.64). 
Binary logistic univariable regression identified only the WD14 gene signature and wound 
duration as independent variables which predicted outcomes at 12 week follow up (Table 
2).  On multivariable analysis, both variables remained significant (WD14: P≤0.001 (odds 
ratio (OR): 12.17); wound duration: P=0.044 (OR: 0.98; R2 0.38; Table 2). 
 
DISCUSSION 
This study has demonstrated the potential of a test quantifying the gene expression of a 
number of key molecules to differentiate between healing and non-healing VLUs. A panel of 
25 genes distinguished between both acute versus chronic wounds and healing versus non-
healing chronic wounds. This panel was reduced to 14 genes, without compromising 
diagnostic power. The WD14 gene signature was able to correctly predict clinical outcomes 
after three months with a sensitivity of 63.6 per cent and a specificity of 85.4 per cent.  
Chronic wounds are costly and a considerable source of morbidity and reduced quality of 
life4. Grading the healing potential of a wound generally relies upon a few well recognised 
but relatively simplistic parameters, such as ulcer size and duration20,21.  Sensitive prognostic 
markers are noticeable by their absence22. Gene expression testing for predicting clinical 
outcome and tailoring treatment has been successfully utilised for a number of 
cancers11,23,24. However, unlike cancer, wound healing remains a practice with few accurate 
predictive tools.   
 
 
Wound edge biopsies are often utilised as part of the standard care of patients with chronic 
wounds, undertaken to exclude occult neoplasm or autoimmune-mediated pathology. They 
cause minimal morbidity, heal rapidly, and do not extend overall ulcer healing times25. 
When comparing chronic wounds with normal skin, molecular markers show much greater 
variability between wound edge tissue compared to wound base tissue, making these 
tissues preferential for genetic typing of the healing potential of wounds9. Given the 
increasing recognition that many chronic wounds are harbouring occult neoplasms26, 
histological interrogation of the wound edge is likely to become commonplace in future 
years. 
Wound healing and cancer share a number of cellular processes, including inflammation, 
cell growth, angiogenesis, formation of fibrous tissue/ECM, and cellular migration17,18. It is 
the control and termination of these processes that separates these two diametrically 
opposed processes. Previous experience in expression profiling of cancer related genes in 
breast and other cancers was drawn upon in the original selection of the 121 candidate 
genes to test as diagnostic markers of wound healing. Of these 121 genes, 25 and 
subsequently 14, were taken forward as a result of their differential expression within a 
cohort of acute and chronic wounds and normal skin to test as a combined signature for 
diagnostic potential. 
A greater wound duration was shown to be associated with a reduced likelihood of healing 
at subsequent follow up and is well documented to be associated with a reduced tendency 
to heal across a variety of observational and randomised studies20. What is not clear is the 
causality wound duration plays, or if by definition, it is simply a marker of wounds which 
show a poor tendency to heal. Despite these difficulties in disentangling cause and effect, 
 
 
these data on wound duration from this study provide further impetus to try and avoid 
chronic wounds which by definition are harder to heal. This supports an aggressive 
approach to wounds whilst they are still young, to try and reduce the proportion of them 
which develop chronicity. 
Prognostic information provided by the genes identified in this study has potential clinical 
utility. Current outcomes for patients with chronic wounds are highly variable, and it is 
difficult to accurately counsel patients as to their individual prognosis. Numerous technical 
advances are now available to treat those with hard-to-heal wounds, including dermal 
substitutes, allogenic cultured skin equivalents and hyperbaric oxygen therapy, although 
these novel devices are generally expensive and often only accessible in tertiary centres35. 
Those with low healing potential should be targeted with more aggressive intervention in 
order to promote wound closure, whilst those predicted as being highly likely to heal can be 
managed with standard regimens. Regular and repeated debridement can also be used in 
those wounds with a low healing propensity, in an attempt to transform static wound edge 
tissues to an active healing phenotype36. Fully powered Randomised Controlled Trials are 
required to show what treatment options are of value for wounds of low healing potential 
as, to date, the data to demonstrate benefits of many interventions does not exist and this 
could be due in part to heterogeneity of the population of patients studied. 
This study has some limitations. The cohort comprises patients reviewed in a tertiary wound 
healing unit, and its applicability in an unselected cohort of patients with wounds is 
unknown.  Patients from the study cohort had a median wound duration of 21 months, 
approximately 50 per cent have deep venous disease, and were generally considered ‘hard 
to heal’ prior to review.  The WD14 tool is therefore developed in a distinct subset of 
 
 
patients with VLUs which limits translation of its usage to uncomplicated VLUs, especially 
when healing rates of >85 per cent over a 24 week period are reported in VLUs of <6 
months duration with superficial venous disease only37. The WD14 would have to 
demonstrate much greater prognostic power in this cohort and external validation in larger 
cohorts of patients before it could be used in standard clinical practice. Further research is 
required to ascertain the most appropriate way of utilising gene signatures in the 
management of patients with chronic wounds. This cohort comprised VLUs alone, although 
chronic wounds of differing aetiologies share many similarities at the molecular and 
biochemical level, and it may be that the WD14 score is able to correctly identify the 
likelihood of wound healing for wounds of different aetiologies. Such work is under 
investigation, whilst also recognising the importance of validating WD14 in a larger cohort of 
VLUs from other centres. However, the results presented here are promising and have been 
validated in a sequential manner with 180 patients in total. The inefficiency in the systems 
of routine care provision make a strong case to support the use of tests to improve targeting 
of specific therapies for hard to heal ulcers, and continuation of simple remedies for wounds 
that have a biological propensity to heal.  The current study adds to this vital area of 
research, highlighting WD14 as a valuable tool in helping to predict outcomes in chronic 
wounds, with the potential to significantly alter how treatment is prioritised in these 
patients, and highlighting the applicability of precision based medicine in wound healing.  
  
 
 
TABLES 
Table 1.  Summary of the three cohorts used for WD14 creation and evaluation.  † Of 17 
samples originally collected, three samples had insufficient RNA/cDNA available to be 
analysed.   
 
 Cohort 
design 
Number of 
patients 
Genes 
examined 
Outcome 
Screening 
Cohort (Ethical 
Approval 
Reference 
Number 
04/WSE02/10) 
Retrospective 
analysis of 
tissue bank 
34:  
acute 
wounds = 10;  
VLUs = 14†; 
normal skin 
= 10 
121 
candidate 
genes 
(Table S2) 
25 genes expressed 
differently between wound 
type - combined as initial 
WD25 gene signature 
Validation 
cohort (Ethical 
Approval 
Reference 
Number 
SJT/C617/08) 
Retrospective 
analysis of 
tissue bank 
71 VLUs;  
20 healed at 
3 months,  
51 non-
healed at 3 
months 
WD25 
(Table S3) 
11 genes which failed to 
differentiate between 
healed and unhealed 
wounds were removed.  
Resultant 14 genes 
combined as WD14 gene 
signature 
Study cohort 
(Ethical 
Approval 
Reference 
Number 
09/WSE02/51) 
Prospective 
controlled 
trial 
85 VLUs;  
41 healing at 
3 months, 
 44 static or 
non-healing 
at 3 months 
WD14 
(Table S4) 
Prognostic power of WD14 
gene signature determined 
 
 
 
Table 2. Univariate and multivariate analysis of wound duration and WD14 gene signature 
score. The WD14 gene signature was significantly predictive of healing outcomes on 
multivariate analysis. A greater wound duration was associated with a reduced likelihood of 
subsequent healing.   NA: Not applicable. 
 
Factor Univariate Multivariate 
P value Odds ratio (95 per 
cent c.i.) 
P value Odds ratio (95 per 
cent c.i.) 
Wound duration  0.053 0.985 (0.970-
1.000) 
0.044 0.983 (0.966-
0.999) 
WD14 gene signature 
score 
<0.001 9.529 (3.315-
27.396 
<0.001 12.166 (3.800-
38.949) 
Age 0.284 0.985 (0.959-
1.012 
NA 
Smoking 0.119 0.317 (0.075-
1.344) 
NA 
Use of antibiotics or 
antimicrobials  
0.146 2.153 (0.766 – 
6.054) 
NA 
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FIGURE LEGENDS 
Figure 1: Flow diagram outlining study design and development of WD14 signature. 
Figure 2: ROC analysis of WD25 signature in a clinical cohort of acute and chronic wounds. 
(A) ROC curve and (B) boxplot presentation of WD25 within the acute (n=10) and chronic 
(n=14) wound cohort. Signature score cut off value (>16) indicated on box plot. 
Figure 3: ROC analysis and comparison of WD25 and WD14 predictive power in chronic 
healing and non-healing wound cohort after 12 weeks. Boxplot presentation of (A) WD25 
signature scores and (B) WD14 signature scores within the chronic healing (n=20) and non-
healing (n=51) clinical wound cohort. Signature score cut off values (A; >16 and B; >8) 
indicated on box plots. (C) ROC curve and AUC comparison of the WD25 and WD14 
predictive tests demonstrating a slight improvement with the WD14 gene expression 
signature.  
Figure 4: ROC analysis of WD14 signature within the study cohort. (A) ROC curve and (B) 
boxplot presentation of WD14 within the healing (n=41) and non-healing (n=44) study 
cohort. Signature score cut off value (>8) indicated on box plot. 
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Processing of biopsies for RNA extraction 
Wound biopsies were sectioned on a Leica cryostat (Leica Microsystems Ltd,. Milton 
Keynes, UK) to a 7µm thickness. For RNA extraction, 50-75 sections were combined and 
homogenised in an RNA extraction solution (TRI Reagent®, Sigma-Aldrich, UK). cDNA 
was generated from the same amount of RNA using a reverse transcription kit (Primer 
Designs, Southampton, England). For the screening and validation cohort, cDNA samples 
were randomly plated in a 96-well plate (Advanced Biotechologies Ltd. (Abgene), Epsom, 
Surrey, UK) for high throughput screening, whilst samples from the study cohort were 
individually stored for batch testing with the WD14 gene signature.  
 
Quantitative gene transcript analysis 
Quantitative polymerase chain reaction (QPCR) gene transcript analysis was undertaken 
using the AmplifluorTM Universal Detection System (Intergen Inc, Oxford, UK).  Specific 
primer sets were designed to amplify a unique region of each target gene transcript and 
tagged with an additional Z-sequence at the 5'-end of one of the primers, which links to the 
complementary FAM-tagged probe, UniprimerTM (Intergen Inc, Oxford, UK). Primers were 
synthesised by Sigma Genesis (Poole, UK, Table S6. In a typical reaction, QPCR mastermix 
(IQ supermix; BioRad Laboratories, Hemel Hempstead, UK), the primer pair, probe and 
cDNA from samples (or negative/positive control template) were included and the reactions 
run on an iCycler real time PCR detection system (BioRad Laboratories, Hemel Hempstead, 
UK). cDNA was denatured and the polymerase activated for 12 minutes at 95oC, followed by 
 
 
100 cycles of: denaturing (95oC for 15 seconds), annealing (55oC for 20 seconds) and 
synthesis (72oC for 15 seconds). The detection of fluorescent signal was carried out at the 
annealing stage and run simultaneously with an internal standard, a purified plasmid coding 
podoplanin, allowing for the calculation of relative expression within the samples in each test 
plate. Such technology has previously been utilised by our group and reported1,2. Three 
housekeeping genes, cytokeratin-19, β-actin and GAPDH, were used in all assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1 Demographic data for patients in the screening cohort. 
 
Wound type Age (Median; range) Sex (per cent male) 
Acute wound 22 (19.5-25.5.) 70 
Chronic wound 69 (64-73) 58.8 
Normal skin 24.5 (22.3-31.8) 30 
 
  
 
 
Table S2.  List names, and accession numbers of gene transcripts tested. 
The biological similarities of cancer and wound healing have been well documented3,4. It 
was hypothesised that genes promoting cancer progression would also be enhanced in 
wounds undergoing healing.  
Gene  Accession number 
AAMP M95627 
Actin NM_001101 
AMFR L35233 
ARP2 AF006082 
BMP10 NM_014482 
BMP15 NM_005448 
BMP7 BC004248 
BMP8 NM_181809 
BMP9 AF188285 
CAR1 NM_001338 
CCN2 NM_001901 
CCN3 NM_002514 
CD24 BC064619 
CD34 M81104 X60172 
CD49F NM_002203 
Chordin V1 AF209929 
Chordin V3 AF283325 
Chordinv2 AF209930 
Claudin-5 NM_003277 
CMG1 AY040325 
CMG2 AY040326 
COM1 NM_012385 
CREBL1 NM_004381 
Cyr61 AF307860 
DRIM NM_014503 
EHM2 AB032179 
Endomucin-2 AB034695 
FAP U09278 
GAPDH NM_002046 
GDF9A NM_005260 
HGFL NM_020998 
IL13 U70981 
IL17A NM_002190 
IL17B NM_014443 
IL17BR AF212365 
IL17C NM_013278 
IL22R BC029273 
IL24 BC009681 
IL4 M13982 
 
 
IL8R U58828 
IL8RB NM_001557 
JAK1 M64174 M35203 
KAI1 U20770 
KISS1 AY117143 
Kiss1R NM_032551  
L1CAM M77640 
LYN BC068551 
NOTICH1 AF308602 
N-WASP  D88460 
OSPA NM_001040058 
OSP-C NM_001040060 
PAR4 AB108448 
PEDF M76979 
PlGF1 X54936 
Psoriasin M86757 
PTPRK AF533875 
RGMa NM_020211 
RGMc BC085604 
RHO GDI-G AF498928 
RHO-8 AF498969 
RHO-C L25081 
ROCK1 D87931 
RON NM_002447 
SATB1 NM_002971 
SATB2 NM_015265 
SDF1 XM_165565 
SHH L38518 
SNAIL AF131208 
ß-Catenin P35222 
SSTR1 L14865 
STYK1 NM_018423 
TEM1 XM_006495 
TEM4 AF378754 
TEM6 AF378756 
TEM7R AF378757 
TEM8 NM_032208 
VEGF E14233 
VEGF-C AF244813 
VEGF-D D89630 
VEGF-R E13256 
VEGF-R2 AF063658 
WAVE1 AF134303 
WAVE2 AB026542 
WAVE3 AB026543 
HGF X16323 
HGFA D14012 
cMET J02958 
 
 
VEGI BD131562 
ADAM1 NR_036636 
ADAM10 NM_001110 
ATF1 NM_005171 
BDNF AF400438 
Neuropilin-1 AF018956 
Neuropilin-2 AF022859 
FAM3C BC046932 
TANK U63830 
Aurora-A D84212 
Aurora-B NM_004217 
PPAR-gamma NM_015869 
P53 M14695 
LOX M94054 
LOX-L2 NM_002318 
LOX-L4 AF395336 
EPLIN AF198454 
HuR U38175 
STYK1 NM_018423 
DR3 U72763 
DcR3 AF104419 
ARP2 AF006082 
IL22 AF279437 
Matrip2 AJ319876 
Matrip1 AF118224 
HAI1 NM_003710 
 HAI2 E12900 
SOCS-1 NM_003745 
SOCS-2 BC010399 
SOCS-3 NM_003955 
SOCS-4 BC060790 
SOCS-5 NM_144949 
SOCS-6 NM_004232 
SOCS-7 XM_371052 
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Table S3. The 25 gene signature list, comprising genes whose expression was significantly 
altered within a cohort of acute and chronic wounds and normal skin. Median, together with 
Q1 and Q3 values are shown. Based on their differential expression, together with our prior 
knowledge, genes were designated either ‘promoting’ of ‘inhibiting’ of wound healing. 
Molecule 
name 
Median 
(Q1-Q3) 
expression 
in Acute 
wounds (n = 
10) 
Median 
(Q1-Q3) 
expression 
in Chronic 
wounds (n 
=14)(Q1-
Q3) 
Median 
(Q1-Q3) 
expression 
in normal 
skin ( n = 
10) 
p-value 
(Krusk
al 
Wallis) 
Expressional 
differences 
between wound 
and normal 
tissues 
Predicted 
effect on 
the wound 
healing  
AMFR 1201 (825-
8139) 
281 (197-
578) 
1097 (257-
2339) 
0.024 Enhanced 
expression in 
acute wounds 
compared to 
chronic  
Promoting 
ARP2 74 (32-236) 2.5 (0.75-
5.50) 
5 (0-28.5) 0.000 Decreased in 
chronic and 
increased in 
acute wounds 
compared to 
normal skin 
Promoting 
β-Catenin 761 (1-
29948) 
0 (0-1) 1 (0-58379) 0.026 Decreased in 
chronic wounds 
compared to 
acute wounds 
Promoting 
BMP15 1 (0-3) 0 (0-0) 0 (0-1) 0.068 Decreased in 
chronic wounds 
compared to 
acute wounds 
Promoting 
CAR1 1676 (255-
9537) 
128 (9.2-
226.7) 
35 (0-292) 0.001 Decreased in 
chronic and 
normal skin 
compared to 
acute wounds 
Promoting 
Claudin-5 14 (5-86) 0 (0-0.25) 0 (0-1.5) 0.001 Increased in 
acute wounds 
compared to 
normal skin and 
chronic wounds 
Promoting 
CREB1l 142 (53-454) 15.5 (8.25-
38.25) 
35 (6-227) 0.004 Decreased in 
chronic and 
increased in 
acute wounds 
compared to 
normal skin 
Promoting 
Endomuci
n-2 
1197 (410-
3357) 
468 (210–
3805) 
63713 
(7835-
221687) 
0.006 Decreased in 
chronic wounds 
Promoting 
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compared to 
acute wounds 
IL17BR 0.055 (0.023-
1.18) 
0.0028 
(0.0006-
0.01) 
0.005 
(0.002-
0.043) 
0.015 Decreased in 
chronic and 
increased in 
acute wounds 
compared to 
normal skin  
Promoting 
IL17C 0 (0-1) 0.01 
(0.0075-
0.0350) 
0.025 (0-
0.138) 
0.027 Decreased in 
chronic and 
acute compared 
to normal skin  
Promoting 
IL22R 1555 (505-
3434) 
302 (143-
627) 
0 (0-175.5) 0.000 Increased in 
both acute and 
chronic wounds 
compared to 
normal skin 
compared to 
normal skin 
Promoting 
IL8RB 34 (3-85) 0.5 (0-
1.125) 
0.5 (0-11) 0.001 Decreased in 
chronic and 
normal skin 
compared to 
acute wounds 
Promoting 
KAI1 395 (161-
11885) 
71.5 (37-
105) 
0 (0-141) 0.001 Increased in 
both acute and 
chronic wounds 
compared to 
normal skin   
Inhibiting   
N-WASP  0.115 (0.016-
0.332) 
0.019 
(0.0012-
0.06) 
0.02 
(0.005-
0.049) 
0.059 Decreased in 
chronic and 
normal skin 
compared to 
acute wounds 
Promoting 
Par4 7 (2-47) 0 (0-2) 2 (0-5) 0.011 High in acute 
wounds 
compared to 
chronic wounds 
Promoting 
PEDF 411 (22-
1858) 
11 (4-125) 1204 (47-
4580) 
0.011 Decreased in 
human wounds 
compared to 
normal skin 
Promoting 
Psoriasin 23891 (326-
337629) 
2 (0-157) 1 (0-13045) 0.01 Decreased in 
chronic and 
normal skin 
compared to 
acute wounds  
Promoting 
PTPRK 132 (37-464) 2 (1-9) 0 (0-50) 0.001 Increased in 
acute and 
chronic wounds 
compared to 
normal skin 
Promoting 
RhoGDI-
G 
31 (14-478) 2 (0.8-12.5) 166 (13-
1145) 
0.009 Decreased in 
human wounds 
Inhibiting 
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compared to 
normal skin 
RON 1 (0-2) 0 (0-0.1) 0 (0-0.45) 0.028 Increased in 
acute wounds 
compared to 
chronic and 
normal skin 
Promoting 
TEM4 135 (63-394) 14 (6-
33.75) 
40 (14.3-
136) 
0.001 High in acute 
wounds 
compared to 
chronic wounds 
Promoting 
TEM7R 11 (8-64) 3.5 (1-4.5) 0 (0-5.5) 0.001 Increased in 
both acute and 
chronic wounds 
compared to 
normal skin 
Promoting 
VEGF-C  16 (9-92) 2.5 (0.75-
6.25) 
7 (3.5-72.7) 0.007 Decreased in 
chronic wounds 
compared to 
acute wounds  
Promoting 
VEGF-D  2 (0-19) 0 (0-0.25) 0 (0-2) 0.021 Decreased in 
chronic and 
normal skin 
compared to 
acute wounds 
Promoting 
WAVE2 0.020 (0.01-
0.59) 
0.009 
(0.0004-
0.012) 
0.017 
(0.0017-
0.06) 
0.275 High in acute 
wounds 
compared to 
chronic wounds 
Promoting 
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Table S4.  Composition of the WD14 gene signature. Genetic markers were divided into two 
groups depending on their anticipated healing impact.   
   Gene  
Promoting wound 
healing 
  
 
ARP2  
CAR1  
Claudin-5  
CREBL1 
Endomucin-2  
IL8RB  
IL17BR  
IL22R  
Psoriasin  
PTPRK  
TEM4  
TEM7R  
VEGF-C  
Inhibiting wound 
healing  
KAI1  
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Table S5 Demographics of cohort used for WD14 
 
 Median Inter-quartile range 
Age 75.0 (years) 63 to 83 
Wound duration 21.0 (months) 9.0 to 49.5 
 
 Frequency  
Sex (male) 40.2 per cent  
  Smokers (active) 22.2 per cent  
Rheumatoid Arthritis 9.7 per cent  
Connective Tissue 
Disease 
1.4 per cent  
Immunosupression 11.3 per cent  
Active cancer 7.0 per cent  
Malnutrition 10.6 per cent  
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Table S6 Primers for the genes comprising the 25 gene signature list (WD25). Primer pairs 
used to detect the GAPDH, CK-19 and Actin housekeeping genes are also listed. 
Primer set Forward Reverse 
IL8rb  
CGTTACCTGGCCATT
GTC 
ACTGAACCTGACCGTACAGCAGGGACAGA
TTCATAGAC 
PEDF  
GGTGCTACTCCTCTG
CATT 
ACTGAACCTGACCGTACAAGAAAGGATCC
TCCTCCTC 
CL5  
TTCCTGGACCACAAC
ATC 
ACTGAACCTGACCGTACACACCGAGTCGT
ACACTTTGC 
RON 
CATCCACCCAGTGCC
AAC 
ACTGAACCTGACCGTACACCACACAGTCA
GCCACAG 
KAI1  
CATTCGAGACTACA
ACAGCA 
ACTGAACCTGACCGTACATCCAGTTGTAGA
AGCTGACC 
RhoGDI 
gamma 
AGTCCTCCTGGCTGA
CAA 
ACTGAACCTGACCGTACACACAGCCTCATC
CAACAC 
N-WASP  
AGTCCCTCTTCACTT
TCCTC 
ACTGAACCTGACCGTACAAGATCTCTGTGG
ATTGTCCT 
Endomucin-2 
AAATGTTGTCACACC
AACAA 
ACTGAACCTGACCGTACAAGCTGTTGACAT
CAGAGACA 
PTPRK 
TATGGCTGTACCTCC
ATTGT 
ACTGAACCTGACCGTACAATATCGTAGCAT
CCCTTCCT 
40 
 
β-CATENIN 
AGGGATTTTCTCAGT
CCTTC 
ACTGAACCTGACCGTACACATGCCCTCATC
TAATGTCT 
IL17C  
CATCTCACCCTGGAG
ATACC 
ACTGAACCTGACCGTACACATCGATACAG
CCTCTGC 
VEGFD  
GCTCCAGTAATGAA
CATGG 
ACTGAACCTGACCGTACAATCTGCTGTTCA
GATCGTT 
WAVE 2  
CAGCTGACTACCCA
ACTGTG 
ACTGAACCTGACCGTACAATCTGCACCAGT
GAAAGG 
TEM4 
GTCTCGTTCAAGCTG
CTG 
ACTGAACCTGACCGTACAGGTGTCCGTGTC
CTCCTC 
BMP 15  
GTGAACCCCTTGACC
AGT 
ACTGAACCTGACCGTACATTGGTATAGTCC
TCGGTTTG 
Psoriasin 
(S100A7)  
AACTTCCCCAACTTC
CTTAG 
ACTGAACCTGACCGTACAAGCAAGGACAG
AAACTCAGA 
IL17BR 
AGTGACTGGGGATA
GTGAAG 
ACTGAACCTGACCGTACACAGAGCACAAC
TGTTCCTTT 
TEM7R 
CTTGATTGGCAGTAT
GGAGT 
ACTGAACCTGACCGTACAGTCTACCGCCTT
GAGAAAG 
CAR1  
ATGGATCTGAAGAA
ATTGGA 
ACTGAACCTGACCGTACAAGACAATTTTTG
CCACTCAT 
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AMFR  
GAAGGTGCGTCCTCT
GAC 
ACTGAACCTGACCGTACATAGGAGGTCTG
CTGCTTCT 
IL22R  
AGATGACTGACAGG
TTCAGC 
ACTGAACCTGACCGTACAGAATCGATCTCA
CTTTGGAG 
CREBL1  
GGGGACTATGAGGA
GATGAT 
ACTGAACCTGACCGTACAGTGGAGGTCTTG
ATGTGAAT 
PAR4  
ACTGAACCTGACCGTA
CAGATCTTACGCTTC
CCTTACC ATGCCAGGAGACGACCTC 
VEGFC 
GCTGCTGCACATTAT
AACAC 
ACTGAACCTGACCGTACAAACTCCTTCCCC
ACATCTAT 
ARP2  
ATTGAGCAAGAGCA
GAAACT 
ACTGAACCTGACCGTACATTCTGGTGCTTC
AAATCTCT 
GAPDH  
CTGAGTACGTCGTGG
AGTC 
ACTGAACCTGACCGTACACAGAGATGATG
ACCCTTTTG 
CK19  
CAGGTCCGAGGTTA
CTGAC 
ACTGAACCTGACCGTACACAGTTTCTGCCA
GTGTGTCTTC 
ACTIN  
CATTAAGGAGAAGC
TGTGCT 
ACTGAACCTGACCGTACAGCTCGTAGCTCT
TCTCCAG 
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